• No results found

The relative biological effectiveness (RBE) of a 200–MeV clinical proton beam

N/A
N/A
Protected

Academic year: 2021

Share "The relative biological effectiveness (RBE) of a 200–MeV clinical proton beam"

Copied!
103
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)
(2)
(3)

ABSTRACT

Cancer therapy with high-energy particles has proved to be beneficial over the last IO years. Protons are regarded as being more advantageous because of their distinctive physical depth dose distribution that allows dose conformation to the tumor while sparing normal tissue. In this study, the relative biological effectiveness (RBE) values for the 200-MeV clinical proton beam at iThemba LABS were measured at strategic positions along a 5 cm Spread-Out-Bragg-Peak (SOBP)~

RBE values w

.

~re

evaluated at the initial plateau of the virgin beam (24.2 mm in Perspex), and at the middle part, distal part and distal edge (12.4% max. dose) along the SOBP (depth in Perspex= 161.4, 181.3 and 207.7 mm respectively). Biological systems used were Chinese hamster ovary cells (CHO-Kl) for both cell survival and micronuclei frequencies as well as human T-lymphocytes for micronuclei frequency analysis. 60Co

y-irradiation served as a reference.

Cell survival measurements yielded RBE values of 1.17 at the distal part and 1.62 at the distal edge (12.4 max. dose). For micronuclei analysis, a limiting RBEap+iay value of 1.3 at the distal part was observed. Using T-lymphocytes, RBEap+/ay values calculated were 2.1, 2.7 and 3.2 at the middle part, distal part and distal edge, respectively.

These results show an increase in RBE with depth of penetration and are explained by an increase in ionization density at the end of the SOBP. This is influenced by a high fraction oflow-energy protons at that position. Protons were found to be most potent per unit dose towards the end as they slow down to a complete stop. It is recommended that .. an RBE value slightly greater than the current 1.1 be applied in therapy.Also, that the less

steep biological effective depth dose curve be taken into account when dose planning.

(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
(47)
(48)
(49)
(50)
(51)
(52)
(53)
(54)
(55)
(56)
(57)
(58)
(59)
(60)
(61)
(62)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80)
(81)
(82)
(83)
(84)
(85)
(86)
(87)
(88)
(89)
(90)
(91)
(92)
(93)
(94)
(95)
(96)
(97)
(98)
(99)
(100)
(101)
(102)
(103)

Referenties

GERELATEERDE DOCUMENTEN

Nevertheless, MSCs of bone marrow origin, either fetal or adult, exhibit a higher chondrogenic potential than fetal lung and placenta derived MSCs, as demonstrated by the

Also for this set of experiments, MSCs-FCS and MSCs-PL were chosen and tested for their genomic situation; in particular four of the eight BM donors were studied at baseline

MSCs from all donors were characterized by morphology, differentiation capacity and immune phenotype at different culture time points, namely P3, P6, P9, P12, P15 and later,

1 However, both primary (defined as lack of hematologic recovery or absence of donor chimerism) and secondary (defined as loss of donor chimerism after initial engraftment) 2

Patients with steroid-resistant, severe, acute GVHD were treated with mesenchymal stem cells, derived with the European Group for Blood and Marrow Transplantation ex-vivo

MSCs from bone marrow (BM) of 7 CD-patients (median age 32 years) were expanded ex vivo in the presence of 5% platelet lysate; cells were investigated for clonogenic

We also investigated the biological/functional properties of UCB-MSCs, in comparison with PL-expanded bone marrow (BM)-MSCs. Success rate of MSC isolation from UCB was in the order

However, at present, no specific marker or combination of markers has been identified that specifically defines true MSCs and ex vivo expanded cells are currently stained with